Actelion continues 2009 growth, but trial delays hurt product pipeline
This article was originally published in Scrip
Executive Summary
Actelion's product pipeline has again suffered setbacks as a number of its programmes have been delayed by FDA requirements and structural issues, the firm announced in its first-half results.